Lyell Immunopharma (LYEL) Earnings Date & Reports

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LYEL is expected to report earnings to rise 94.55% to -214 cents per share on August 12

Lyell Immunopharma LYEL Stock Earnings Reports

Q2'26

Est.

$-2.14

Q1'26

Missed

by $0.92

Q4'25

Missed

by $6.69

Q3'25

Missed

by $1.96

Q2'25

Missed

by $2.73

The last earnings report on May 06 showed earnings per share of -110 cents, missing the estimate of -18 cents. With 360.10K shares outstanding, the current market capitalization sits at 296.93M.

View a ticker or compare two or three

Compare

LYEL

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for LYEL